Business01 December, 20253 min read
UK Government Agrees To Raise NHS Drug Prices 25% To Secure Zero-Tariff Deal With US
This article is an automated aggregation of coverage from news outlets. Our editorials offer in-depth analysis curated by the NewsCord team.
US will keep tariffs on UK-made medicines at 0% for three years UK agreed the NHS will increase spending on new medicines in exchange
5 outlets told this the same way.
UK–US pharmaceutical tariff deal
The UK government has agreed to a deal with the United States that removes tariffs on pharmaceuticals for at least three years in exchange for the UK committing to raise NHS spending on medicines by about 25%. Both sides described a 0% tariff arrangement on pharmaceuticals for at least three years, and officials framed the pact as encouraging cross-Atlantic investment and jobs. Newsday reported the UK and US struck a deal exempting UK-origin pharmaceuticals, pharmaceutical ingredients and medical technology from import tariffs for at least three years.
“Both sides agreed a 0% tariff arrangement on pharmaceuticals for at least three years; the UK says this is the lowest rate offered to any country. The US administration said the move will encourage more investment by UK drug firms in the US and create jobs.”
The London Evening Standard noted the UK says this is the lowest rate offered to any country and the US administration said it will encourage more investment by UK drug firms in the US and create jobs. The Northwich Guardian likewise stated the UK has agreed to grant US pharmaceutical imports a 0% tariff for three years and that the Trump administration said the pact will encourage UK drug firms to invest more in the US and create jobs.
UK NHS drug spending increase
A central UK commitment in the accord is to raise the upper threshold for buying new medicines by 25%. This change expands the NHS’s ability to approve treatments previously judged not cost-effective, including some breakthrough cancer therapies and rare-disease drugs. The commitment will increase overall spending on new and effective treatments by about 25%.
The London Evening Standard specified the 25% raise and explained it will allow some previously rejected treatments to be approved. Newsday described the UK's pledge as its first major increase in over two decades. The Northwich Guardian also confirmed the NHS will increase its spending on medicines as part of the arrangement.
NHS drug pricing changes
The agreement also adjusts how drug pricing and NHS repayments will operate. The London Evening Standard reports the deal lowers the repayment rate on NHS drug prices to 15% from 2026, the share drug companies must repay to prevent the NHS overspending its branded-medicines budget. That technical detail is unique to the Evening Standard; Newsday focuses on the tariff exemption and investment and job pledges, while the Northwich Guardian repeats the core tariff and spending exchange without mentioning the repayment rate.
“The agreement lowers the repayment rate on NHS drug prices to 15% from 2026 — the share drug companies must repay to prevent the NHS overspending its branded‑medicines budget.”
Coverage of US–UK drug pact
London Evening Standard highlighted warnings from US pharmaceutical companies and diplomats that American firms could cut UK investment unless the NHS paid more for drugs, and it cited recent pauses or cancellations of UK investments by companies such as Merck and AstraZeneca. Newsday said the deal included a reciprocal element — that U.K. drug companies agreed to boost investment and job creation in the U.S., effectively framing it as a quid pro quo.
Northwich Guardian echoed the US administration’s stated aim that the pact will encourage UK drug firms to invest more in the US and create jobs, but it did not include the examples of paused investments. Overall, coverage varied between emphasizing investor warnings about UK access and framing the pact as a mutual investment-for-access agreement.
Reactions to drug deal
Government and industry reactions differed in tone across the reporting. Ministers were quoted saying the deal would speed UK patients' access to cutting-edge drugs and protect the domestic life-sciences sector, and the ABPI called it 'an important step for patient access to innovative medicines' in the London Evening Standard.
“Ministers framed the deal as speeding UK patient access to cutting‑edge drugs and protecting the domestic life‑sciences sector. The ABPI called it an important step for patient access to innovative medicines.”
Newsday summarised both governments as characterising the agreement 'as a win'. The Northwich Guardian reported the core facts and the administration's claim more tersely, without those additional endorsements.